T1	PROC 1 30	Estudio piloto de la eficacia
#1	AnnotatorNotes T1	C0031928; Pilot Projects; Research Activity + C1707887; Efficacy Study; Research Activity
T2	CHEM 82 92	artesunato
#2	AnnotatorNotes T2	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T3	CHEM 93 103	mefloquina
#3	AnnotatorNotes T3	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T4	CHEM 104 114	primaquina
#4	AnnotatorNotes T4	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T5	DISO 123 156	malaria por Plasmodium falciparum
#5	AnnotatorNotes T5	C0024535; Malaria, Falciparum; Disease or Syndrome
T6	PROC 175 186	tratamiento
#6	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T7	DISO 193 218	malaria por P. falciparum
#7	AnnotatorNotes T7	C0024535; Malaria, Falciparum; Disease or Syndrome
T8	DISO 276 287	transmisión
#8	AnnotatorNotes T8	C0242781; disease transmission; Pathologic Function
T9	CHEM 336 346	artesunato
#9	AnnotatorNotes T9	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T10	CHEM 347 357	mefloquina
#10	AnnotatorNotes T10	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T11	CHEM 372 382	primaquina
#11	AnnotatorNotes T11	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T12	PROC 425 444	Evaluar la eficacia
#12	AnnotatorNotes T12	C1707887; Efficacy Study; Research Activity
T13	CHEM 481 491	artesunato
#13	AnnotatorNotes T13	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T14	CHEM 492 502	mefloquina
#14	AnnotatorNotes T14	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T15	CHEM 503 513	primaquina
#15	AnnotatorNotes T15	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T16	CHEM 516 526	artesunato
#16	AnnotatorNotes T16	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T17	CHEM 527 537	mefloquina
#17	AnnotatorNotes T17	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T18	DISO 555 562	malaria
#18	AnnotatorNotes T18	C0024530; Malaria; Disease or Syndrome
T19	PROC 639 663	Ensayo clínico aleatorio
#19	AnnotatorNotes T19	C0206034; Clinical Trials, Randomized; Research Activity
T20	PROC 669 681	tratamientos
#20	AnnotatorNotes T20	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T21	PROC 733 767	seguimiento clínico-parasitológico
T22	PROC 849 858	protocolo
#21	AnnotatorNotes T22	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T23	CHEM 1045 1055	artesunato
#22	AnnotatorNotes T23	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T24	CHEM 1056 1066	mefloquina
#23	AnnotatorNotes T24	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T25	CHEM 1076 1086	primaquina
#24	AnnotatorNotes T25	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T26	DISO 1092 1103	parasitemia
#25	AnnotatorNotes T26	C0242723; Parasitemia; Disease or Syndrome
T27	DISO 1109 1115	fiebre
#26	AnnotatorNotes T27	C0015967; Fever; Sign or Symptom
T28	PROC 1165 1176	tratamiento
#27	AnnotatorNotes T28	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T29	CHEM 1255 1265	primaquina
#28	AnnotatorNotes T29	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T30	PROC 1284 1295	seguimiento
#29	AnnotatorNotes T30	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T31	CHEM 1352 1362	primaquina
#30	AnnotatorNotes T31	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T32	CHEM 1452 1462	artesunato
#31	AnnotatorNotes T32	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T33	CHEM 1463 1473	mefloquina
#32	AnnotatorNotes T33	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T34	CHEM 1494 1504	artesunato
#33	AnnotatorNotes T34	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T35	CHEM 1505 1515	mefloquina
#34	AnnotatorNotes T35	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T36	CHEM 1516 1526	primaquina
#35	AnnotatorNotes T36	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T37	CHEM 1588 1598	primaquina
#36	AnnotatorNotes T37	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T38	CHEM 1646 1656	artesunato
#37	AnnotatorNotes T38	C0052432; artesunate; Organic Chemical · Pharmacologic Substance
T39	CHEM 1657 1667	mefloquina
#38	AnnotatorNotes T39	C0025153; mefloquine; Organic Chemical · Pharmacologic Substance
T40	DISO 1676 1701	malaria por P. falciparum
#39	AnnotatorNotes T40	C0024535; Malaria, Falciparum; Disease or Syndrome
T41	PROC 1745 1757	evaluaciones
#40	AnnotatorNotes T41	C1261322; Evaluation procedure; Health Care Activity
T42	CHEM 1778 1780	PQ
#41	AnnotatorNotes T42	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T43	DISO 1538 1551	gametocitemia
T44	LIVB 58 69	gametocitos
#42	AnnotatorNotes T44	C3662449; Genus Plasmodium gametocyte; Eukaryote
T45	LIVB 205 218	P. falciparum
#43	AnnotatorNotes T45	C0032150; Plasmodium falciparum; Eukaryote
T46	Date 292 296	2006
T47	LIVB 401 412	gametocitos
#44	AnnotatorNotes T47	C3662449; Genus Plasmodium gametocyte; Eukaryote
T48	LIVB 541 550	pacientes
#45	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T50	LIVB 581 594	P. falciparum
#46	AnnotatorNotes T50	C0032150; Plasmodium falciparum; Eukaryote
T51	Duration 771 812	los días 1, 2, 3, 7, 14, 21, 28, 35, y 42
T52	Date 899 912	abril de 2007
T53	Date 915 930	febrero de 2008
T54	LIVB 935 944	pacientes
#47	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	Neg_cue 1072 1075	sin
T56	Date 1151 1161	tercer día
T57	LIVB 1190 1199	pacientes
#48	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	LIVB 1219 1230	gametocitos
#49	AnnotatorNotes T58	C3662449; Genus Plasmodium gametocyte; Eukaryote
T59	Date 1270 1280	tercer día
T60	LIVB 1327 1336	pacientes
#50	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Neg_cue 1363 1365	no
T62	LIVB 1375 1386	gametocitos
#51	AnnotatorNotes T62	C3662449; Genus Plasmodium gametocyte; Eukaryote
T63	LIVB 1432 1441	pacientes
#52	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Duration 1552 1562	una semana
T65	Neg_cue 1584 1587	sin
T66	LIVB 1688 1701	P. falciparum
#53	AnnotatorNotes T66	C0032150; Plasmodium falciparum; Eukaryote
T68	Date 1737 1744	futuras
T69	LIVB 1829 1840	gametocitos
#54	AnnotatorNotes T69	C3662449; Genus Plasmodium gametocyte; Eukaryote
T70	LIVB 135 156	Plasmodium falciparum
#55	AnnotatorNotes T70	C0032150; Plasmodium falciparum; Eukaryote
T49	PROC 952 962	reclutados
#56	AnnotatorNotes T49	C0242800; Patient Recruitment; Research Activity
A1	Assertion T25 Negated
A2	Assertion T62 Negated
A3	Assertion T37 Negated
R1	Negation Arg1:T55 Arg2:T25	
R2	Negation Arg1:T65 Arg2:T37	
R3	Negation Arg1:T61 Arg2:T62	
T67	Neg_cue 563 565	no
T71	Quantifier_or_Qualifier 566 576	complicada
A4	Assertion T71 Negated
#57	AnnotatorNotes T71	C0231242; Complicated; Functional Concept
R4	Negation Arg1:T67 Arg2:T71	
R5	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T71	
R6	Experiences Arg1:T48 Arg2:T18	
R7	Causes Arg1:T50 Arg2:T18	
T72	Observation 40 47	efectos
#58	AnnotatorNotes T72	C1518681; Outcome of Therapy; Finding (?)
R8	Combined_with Arg1:T2 Arg2:T3	
R9	Combined_with Arg1:T3 Arg2:T4	
R10	Causes Arg1:T2 Arg2:T72	
R11	Experiences Arg1:T44 Arg2:T72	
R12	Causes Arg1:T70 Arg2:T5	
R14	Experiences Arg1:T45 Arg2:T7	
R16	Combined_with Arg1:T9 Arg2:T10	
R17	Combined_with Arg1:T10 Arg2:T11	
R18	Overlap Arg1:T9 Arg2:T46	
R19	Overlap Arg1:T10 Arg2:T46	
R20	Overlap Arg1:T11 Arg2:T46	
R21	Combined_with Arg1:T13 Arg2:T14	
R22	Combined_with Arg1:T14 Arg2:T15	
R23	Combined_with Arg1:T16 Arg2:T17	
R24	Experiences Arg1:T48 Arg2:T13	
R25	Experiences Arg1:T48 Arg2:T16	
T73	Quantifier_or_Qualifier 699 719	de forma supervisada
R26	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T73	
R27	Overlap Arg1:T21 Arg2:T51	
R30	After Arg1:T49 Arg2:T52	
R31	Before Arg1:T49 Arg2:T53	
R32	Experiences Arg1:T54 Arg2:T49	
R33	Combined_with Arg1:T23 Arg2:T24	
R34	Combined_with Arg1:T24 Arg2:T25	
R35	Experiences Arg1:T54 Arg2:T23	
R36	Experiences Arg1:T54 Arg2:T26	
R37	Experiences Arg1:T54 Arg2:T27	
R40	Before Arg1:T27 Arg2:T56	
R41	Before Arg1:T26 Arg2:T56	
R42	Overlap Arg1:T28 Arg2:T56	
R43	Used_for Arg1:T23 Arg2:T28	
R44	Experiences Arg1:T57 Arg2:T28	
R45	Experiences Arg1:T57 Arg2:T23	
R46	Experiences Arg1:T57 Arg2:T27	
R47	Experiences Arg1:T57 Arg2:T26	
R48	Experiences Arg1:T57 Arg2:T49	
R49	Experiences Arg1:T54 Arg2:T28	
R50	Overlap Arg1:T30 Arg2:T59	
R51	Experiences Arg1:T60 Arg2:T31	
R52	Experiences Arg1:T63 Arg2:T32	
R53	Combined_with Arg1:T32 Arg2:T33	
R54	Combined_with Arg1:T34 Arg2:T35	
R55	Combined_with Arg1:T35 Arg2:T36	
R58	Combined_with Arg1:T38 Arg2:T39	
R59	Causes Arg1:T66 Arg2:T40	
R60	Overlap Arg1:T41 Arg2:T68	
R63	Before Arg1:T34 Arg2:T64	
R64	Before Arg1:T37 Arg2:T64	
#59	AnnotatorNotes T68	C0016884; Future; Temporal Concept
A5	Experiencer T63 Patient
A6	Experiencer T60 Patient
A7	Experiencer T57 Patient
A8	Experiencer T48 Patient
A9	Experiencer T54 Patient
A10	Status T41 Future
